Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 7/20 | 0.79 |
| ▸ | TFPI | P10646 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nociceptin-Nh2 SCHEMBL30033176 | 0.97 | OPRL1 (0.79) | OPRL1TFPI | |
| Nociceptin SCHEMBL29356402 | 0.91 | OPRL1 (0.66) | OPRL1TFPI | |
| SCHEMBL31536446 | 0.88 | OPRL1 (0.78) | OPRL1 | |
| SCHEMBL29355633 | 0.88 | OPRL1 (0.78) | OPRL1 | |
| SCHEMBL31536447 | 0.88 | OPRL1 (0.78) | OPRL1 | |
| SCHEMBL31060486 | 0.88 | OPRL1 (0.69) | OPRL1TFPI | |
| SCHEMBL29483943 | 0.88 | OPRL1 (0.65) | OPRL1TFPI | |
| SCHEMBL30435652 | 0.86 | TFPI (0.61) | OPRL1TFPI | |
| SCHEMBL30662329 | 0.84 | TFPI (0.61) | OPRL1TFPIOPRM1OPRD1OPRK1 | |
| Dynorphin B SCHEMBL29374545 | 0.84 | OPRD1 (0.61) | OPRL1TFPIOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 837 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| US-12566183-B2 | Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders | NANOSOMIX, INC. (US) | 2026-03-03 | — | — | US | claimed |
| US-20250263728-A1 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | Wyvern Pharmaceuticals Inc. (CA) | 2025-08-21 | — | — | US | claimed |
| US-20250177644-A1 | Systems and Methods for Expression and Delivery of Proteinaceous Species | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-06-05 | — | — | US | claimed |
| CN-120026043-A | Recombinant filamentous fungus transformant screening method based on mesogenic fungus resistance | 华南理工大学 | 2025-05-23 | — | — | CN | claimed |
| US-20250154113-A1 | Microcrystalline Diketopiperazine Compositions and Methods | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2025-05-15 | — | — | US | claimed |
| US-12297227-B2 | Method for extracting target protein from biological sample and method for analyzing target protein | MEDIFORD CORPORATION (JP) | 2025-05-13 | — | — | US | claimed |
| WO-2025085826-A1 | ACTIVATION OF ORL1: A NOVEL THERAPY TO PREVENT HEART FAILURE PROGRESSION | BAYLOR COLLEGE OF MEDICINE (US) | 2025-04-24 | — | — | WO | claimed |
| CN-119455000-A | Triazine compound, conjugate thereof, preparation method and application | 四川科伦博泰生物医药股份有限公司 | 2025-02-18 | — | — | CN | claimed |
| US-12173004-B2 | Pharmaceutical compositions comprising heterocycle fused gamma carboline prodrugs | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-12-24 | — | — | US | claimed |
| US-20220372035-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2022-11-24 | — | — | US | claimed |
| CN-115335122-A | Identification of compounds and their use in the treatment and prevention of severe acute respiratory syndrome coronavirus 2 | 万带兰制药公司 | 2022-11-11 | — | — | CN | claimed |
| EP-3613423-B1 | COMPOSITIONS OF HYALURONAN WITH HIGH ELASTICITY AND USES THEREOF | MATRIX BIOLOGY INST (US) | 2022-10-26 | — | — | EP | claimed |
| US-20220296591-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2022-09-22 | — | — | US | claimed |
| CN-114796446-A | Use of orphanin peptides for the treatment of ketamine addiction | 沃肽生物科技(山东)有限公司 | 2022-07-29 | — | — | CN | claimed |
| EP-3587404-B1 | MICROCRYSTALLINE DIKETOPIPERAZINE COMPOSITIONS, METHODS FOR PREPARATION AND USE THEREOF | MANNKIND CORP (US) | 2022-07-13 | — | — | EP | claimed |
| US-11376249-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-07-05 | — | — | US | claimed |
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | claimed |
| US-20220105135-A1 | METHODS AND COMPOSITIONS FOR THE MODULATION OF OPIOID SIGNALING IN THE TUMOR MICROENVIRONMENT | DANA-FARBER CANCER INSTITUTE, INC. | 2022-04-07 | — | — | US | claimed |
| US-20220048868-A1 | Microcrystalline Diketopiperazine Compositions and Methods | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2022-02-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12173004-B2 | Pharmaceutical compositions comprising heterocycle fused gamma carboline prodrugs | OPRD1, OPRK1, HTR2C | OPRL1 6/4885TFPI 1723/4885OPRM1 5/4885 |
| US-11376249-B2 | Organic compounds | OPRD1, OPRK1, OPRM1 | OPRL1 4/4885TFPI 1289/4885OPRM1 3/4885 |
| US-20220372035-A1 | ORGANIC COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRL1 4/4885TFPI 1162/4885OPRM1 2/4885 |
| US-12566183-B2 | Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders | CD63, SYPL1, SNAP23 | OPRL1 290/4885TFPI 4686/4885OPRM1 1237/4885 |
| US-20220048868-A1 | Microcrystalline Diketopiperazine Compositions and Methods | RRP15, DKK1, SPOP | OPRL1 2827/4885TFPI 2158/4885OPRM1 3137/4885 |
| US-20250154113-A1 | Microcrystalline Diketopiperazine Compositions and Methods | RRP15, DKK1, SPOP | OPRL1 2827/4885TFPI 2158/4885OPRM1 3137/4885 |
| US-20220296591-A1 | ORGANIC COMPOUNDS | OPRD1, OPRK1, OPRM1 | OPRL1 4/4885TFPI 1289/4885OPRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.